Table 2.
Response Assessment
| Overall (n = 42) | Favorable risk (n = 17) * | Intermediate risk (n = 6) * | Adverse risk (n = 19) * | |
|---|---|---|---|---|
| Overall response rate (CR + CRi + PR) | 92.9% (91.6–94.1) [39] | 94.1% (91.5–96.7) [16] | 83.3% (64.2–100) [5] | 94.7% (92.7–96.7) [18] |
| Composite complete remission rate | 90.5% (89.3–91.6) [38] | 94.1% (91.5–96.7) [16] | 83.3% (64.2–100) [5] | 89.5% (85.5–93.5) [17] |
| CR | 88.1% (37/42) | 94.1% (16/17) | 83.3% (5/6) | 84.2% (16/19) |
| CRi | 2.4% (1/42) | 0 | 0 | 5.3% (1/19) |
| PR | 2.4% (1/42) | 0 | 0 | 5.3% (1/19) |
| Died | 2.4% (1/42) | 0 | 0 | 5.3% (1/19) |
| MRD (-) after induction by flow cytometry | 87.9% (95% CI 84.9–90.8; 29/33) | |||
| Responders that received allo-HSCT | 2/41(4.9%) | |||
| Time to blood cell count recovery after induction, days | ||||
| Time to absolute neutrophil count ≥ 0.5 × 109/L, days | 13 (5–26) | |||
| Time to absolute platelet count ≥ 30 × 109/L, days | 12 (8–26) | |||
| Even free survival, | ||||
| Median, months | NR | NR | NR | NR |
| 12-month, % (95% CI) | 82.7% (95% CI: 79.4–86.1%) | 88.9% (95%CI: 83.7–94.2) | 100% | 70.3% (95%CI: 64.7–76.0) |
| Overall survival | ||||
| Median, months | NR | NR | NR | NR |
| 12-month, % (95% CI) | 83.1% (95% CI: 78.8–87.4%) | 87.5% (95%CI: 81.7–93.4) | 100% | 70.7% (95%CI: 62.2–79.2) |
* = Prognostic stratification according to European Leukemia Net 2022 risk category